Results 21 to 30 of about 28,326 (256)

Circulating biomarkers in malignant pleural mesothelioma

open access: yesExploration of Targeted Anti-tumor Therapy, 2020
Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage.
Giuseppe Viscardi   +6 more
doaj   +1 more source

Assessment of ctDNA tumor fraction threshold.

open access: yes, 2023
Each dot represents a sample or a pair of samples (BC: breast cancer, GC: gastrointestinal cancer, SC: sarcoma, MN: melanoma). The numbers following tm (tumor) and ct (ctDNA) indicate the sample collection time points, which are provided in S1–S3 Tables ...
Julanee Leenanitikul (17283511)   +12 more
core   +1 more source

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

open access: yesCancer Biology & Medicine, 2021
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC. This
Anjie Zhu   +19 more
doaj   +1 more source

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. [PDF]

open access: yes, 2018
Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-associated genomic aberrations in peripheral blood. This type of minimally-invasive molecular interrogation has the potential to guide subsequent treatment selection ...
Tilman Todenhöfer   +9 more
core   +1 more source

Minimally invasive differential diagnosis of melanocytic intraocular neoplasms

open access: yesРоссийский офтальмологический журнал, 2023
Purpose: to analyze the mutation frequency of the GNAQ/GNA11 gene in circulating tumor DNA and genotypes of the polymorphic marker C3435T of the ABCB1 gene in a large sample of patients with intraocular melanocytic neoplasms (IMN).Material and methods ...
A. Yu. Tsygankov   +4 more
doaj   +1 more source

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

open access: yes, 2021
Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse.
Bellmunt Molins, Joaquim, 1959-   +2 more
core   +1 more source

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy

open access: yesCancer Biology & Medicine, 2019
As immunotherapy has gained increasing interest as a new foundation for cancer therapy, some atypical response patterns, such as pseudoprogression and hyperprogression, have garnered the attention of physicians. Pseudoprogression is a phenomenon in which
Wenxiao Jia   +4 more
doaj   +1 more source

Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements

open access: yesCells, 2019
In recent years, the introduction of new molecular techniques in experimental and clinical settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) analysis and liquid biopsy as novel promising strategies for the early ...
Natalia O. Tuaeva   +12 more
doaj   +1 more source

Impact of linker histone in the formation of ambochlorin-calf thymus DNA complex: Multi-spectroscopic, stopped-flow, and molecular modeling approaches [PDF]

open access: yesIranian Journal of Basic Medical Sciences, 2021
Objective(s): This study aimed to evaluate the role of the linker histone (H1) in the binding interaction between ambochlorin (Amb), and calf thymus DNA (ctDNA) as binary and ternary systems.
Azam Askari   +8 more
doaj   +1 more source

Survival of Lung Adenocarcinoma Patients with Tyrosine Kinase Inhibitor Therapy Based on EGFR Mutation Status in Tumor and Plasma Samples

open access: yesIndonesian Journal of Cancer, 2023
Background:The prognosis for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is greatly improved when treated with tyrosine kinase inhibitor (TKI).
Haryati Haryati   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy